EMA/735668/2010

European Medicines Agency decision

P/269/2010

of 26 November 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for insulin detemir (Levemir) (EMEA-000412-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

European Medicines Agency decision

P/269/2010

of 26 November 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for insulin detemir (Levemir) (EMEA-000412-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Novo Nordisk A/S on 6 November 2008 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 November 2010, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for insulin detemir (Levemir), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for insulin detemir (Levemir), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for insulin detemir (Levemir), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Novo Nordisk A/S, Novo allé, 2880 Bagsvaerd, Denmark.

Done at London, 26 November 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/591252/2010

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-000412-PIP01-08

Scope of the application

Active substance(s):

Insulin detemir

Invented name:

Levemir

Condition(s):

Treatment of Type I Diabetes Mellitus

Treatment of Type II Diabetes Mellitus

Authorised indication(s): see Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Novo Nordisk A/S

Information about the authorised medicinal product: see Annex II

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Novo Nordisk A/S submitted for agreement to the European Medicines Agency on 6 November 2008 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

The procedure started on 11 December 2008

Supplementary information was provided by the applicant on 26 August 2010

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation,
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population, or occurs only in the adult population, and with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 12 November 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan.

1. Waiver

1.1. Condition: Treatment of Type I Diabetes Mellitus

The waiver applies to:

- Children from birth to less than one year of age,
- for insulin detemir, solution for injection, subcutaneous use,
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfill a therapeutic need of the paediatric population.

1.2. Condition: Treatment of Type II Diabetes Mellitus

The waiver applies to:

- Children from birth to less than 10 years of age,
- for insulin detemir, solution for injection, subcutaneous use,
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of type I diabetes mellitus

2.1.1. Indication(s) targeted by the PIP

Treatment of type I diabetes mellitus

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Studies

Area	Number of studies	Description
Quality		Not applicable.
Non-clinical		Not applicable.
Clinical	4	Study #1: 52-Week, Multinational, Multi-Centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Detemir and NPH Insulin in Children and Adolescents 2-16 years with Type 1

Area	Number of studies	Description
		Diabetes on a Basal-Bolus Regimen with Insulin Aspart as Bolus Insulin (NN304-1689) Study #2: 52-Week, Multinational, Multi-Centre, Open-Labelled Extension Trial of Insulin Detemir in Children and Adolescents 3-17 years with Type 1 Diabetes on a Basal-Bolus Regimen with Insulin Aspart as Bolus Insulin (NN304-1690) Study #3: 6 + 6-month multi-national, multi-centre, open-label, randomised, parallel-group study comparing the efficacy and safety of insulin degludec (IDeg) and insulin detemir, both in combination with mealtime insulin aspart, in children and adolescents with type 1 diabetes mellitus, aged 1 to less than 18 years of age (NN1250-3561) Study #4: PK modelling study in children from 1 to less than 18 years of age, compared to adults, all with type 1 diabetes mellitus.

2.2. Condition: Treatment of type II diabetes mellitus

2.2.1. Indication(s) targeted by the PIP

Treatment of type II diabetes mellitus

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 10 to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Solution for injection

2.2.4. Studies

Area	Number of studies	Description
Quality		Not applicable.
Non-clinical		Not applicable.
Clinical	5	Study #1: same as for condition "treatment of type I diabetes mellitus" Study #2: same as for condition "treatment of type I diabetes mellitus" Study #3: same as for condition "treatment of type I diabetes mellitus" Study #4: same as for condition "treatment of type I diabetes mellitus" Study #5: Extrapolation and modelling study, to extend efficacy results in adults with type 2 diabetes mellitus and children and adolescents with type

Area	Number of studies	Description
		1 diabetes mellitus, to children and adolescents with type 2 diabetes mellitus.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By July 2013
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Type I diabetes mellitus

   Authorised indications:

   Treatment of diabetes mellitus in adults and adolescents and children aged 6 - 17 years.

2. Treatment of Type II diabetes mellitus

   Authorised indications:

   Treatment of diabetes mellitus in adults and adolescents and children aged 6 - 17 years.

EU Number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Content (concentration)	Package size
EU/1/04/278/001	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) (Penfill)	3 ml	1 cartridge
EU/1/04/278/002	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) (Penfill)	3 ml	5 cartridges
EU/1/04/278/003	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) (Penfill)	3 ml	10 cartridges
EU/1/04/278/004	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) in pre-filled pen (FlexPen)	3 ml	1 pre-filled pen
EU/1/04/278/005	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) in pre-filled pen (FlexPen)	3 ml	5 pre-filled pens
EU/1/04/278/006	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) in pre-filled pen (FlexPen)	3 ml	10 pre-filled pens
EU/1/04/278/007	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) in pre-filled pen (InnoLet)	3 ml	1 pre-filled pen
EU/1/04/278/008	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) in pre-filled pen (InnoLet)	3 ml	5 pre-filled pens
EU/1/04/278/009	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) in pre-filled pen (InnoLet)	3 ml	10 pre-filled pens
EU/1/04/278/010	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) in pre-filled pen (FlexPen) with needle	3 ml	1 pre-filled pen + 7 NovoFine needles
EU/1/04/278/011	Levemir	100 U/ml	Solution for injection	Subcutaneous use	cartridge (glass) in pre-filled pen (FlexPen) with needles	3 ml	1 pre-filled pen + 7 NovoTwist needles